Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have covered the stock in the last year […]

Related Keywords

Switzerland , Los Angeles , California , United States , New York , Swiss , Leerink Partnrs , Stifel Nicolaus , Congress Asset Management Co , Nasdaq , Los Angeles Capital Management , York State Common Retirement Fund , Relay Therapeutics Inc , Swiss National Bank , Relay Therapeutics , Get Free Report , National Bank , Asset Management , Angeles Capital Management , Get Free , Relay Therapeutics Daily , Nasdaq Rlay , Arlay , Medical , Ratings , Consensus ,